Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company with a market capitalization of $503.56 million focused on ...

Type a few symbols and Take a Trial. The signals for these will appear immediately on your My Stocks Page; add more too.

(ETNB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ed Arce from H.C.

Weiss Ratings reiterated their sell (d-) rating on shares of 89bio (NASDAQ:ETNB – Free Report) in a research note released on Saturday,Weiss Ratings reports. A number of other research analysts also ...

Inc.'s results from ENTRUST study on pegozafermin for Severe Hypertriglyceridemia expected in 2025. Click for this updated ...

In this article, we are going to take a look at where 89bio, Inc. (NASDAQ:ETNB) stands against the other small-cap biotech stocks. Revolutionizing Healthcare and Economy: The Rapid Growth of ...

These purchases signal continued confidence in 89bio's prospects, as the company continues its work in pharmaceutical ...

Leerink Partners analyst Thomas Smith has maintained their bullish stance on ETNB stock, giving a Buy rating on January 2.Stay Ahead of the ...

Nov. 26, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative ...

Completed enrollment in Phase 3 ENTRUST trial in patients with severe hypertriglyceridemia (SHTG); topline 26-week data expected in the second half of 2025 – – The Phase 3 ENLIGHTEN program in ...

New post-hoc analyses reinforce pegozafermin’s potential anti-fibrotic effects and the potential utility of non-invasive tests which correlate to histological endpointsSAN FRANCISCO, Nov. 15, 2024 ...